Yida Lafeng (依达拉奉)依达拉奉
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 南京长澳制药有限公司Chinese legal name: 南京长澳制药有限公司
主要成分Active Ingredients
- 依达拉奉Yida Lafeng
药物知识说明
依达拉奉是一种在国家药监局注册认定的药品。该药品含有依达拉奉-1fc53727等成分。
该药品关联的活性成分包括：依达拉奉Yida Lafeng。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：南京长澳制药有限公司Chinese legal name: 南京长澳制药有限公司。
您可以探索含有相同成分的其他药品：依达拉奉-1fc53727成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 依达拉奉) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 依达拉奉Yida Lafeng.
Manufacturers recorded for this product: 南京长澳制药有限公司Chinese legal name: 南京长澳制药有限公司.
Explore other medicines containing the same ingredient: 依达拉奉 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 依达拉奉Recorded Chinese name: 依达拉奉
- 规格Specification: －－－－
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 南京长澳制药有限公司Chinese legal name: 南京长澳制药有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20110010
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20110010
Manufacturer
Chinese legal name: 南京长澳制药有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20110010
生产企业
南京长澳制药有限公司(国产)
适应症
本品可清除自由基，抑制脂质过氧化，从而抑制脑细胞(血管内皮细胞、神经细胞)的氧化障碍，抑制梗死周边领域使血流量下降，作用于脑梗死急性期，抑制脑水肿、脑梗死、神经症状、迟发性神经元死亡等缺血性脑血管障碍的发生和进展(恶化)，从而发挥保护作用。
用法用量
通常成人依达拉奉30mg，2次/d，用时以适量的生理盐水稀释，30min内静脉滴注完。发病后24h内开始给药，疗程为14天。
不良反应
急性肾功能衰竭、肝功能障碍、黄疸、血小板减少、弥散性血管内凝血(DIC)。注射部位发疹、红肿，疱疹，瘙痒感，嗳气，发热，热感，血压上升，血清胆固醇升高，血清胆固醇降低，三酰甘油升高，血清总蛋白减少，肌酸激酶(CK)、肌酸磷酸激酶(CPK)降低，血清钙低下。
禁忌
既往对本品有过敏史的患者，重度肾功能衰竭患者禁用。妊娠或可能妊娠妇女禁用本药。
注意事项
本品原则上必须用生理盐水稀释。不要和高能量输液、氨基酸制剂混合或由一条通道静脉滴注。勿与抗痉挛注射液、坎利酸钾混合。本品给药过程中或给药后，有脑栓塞再发和脑出血的报道。高龄患者的生理功能低下，出现不良反应时应中止给药并适当处理。特别是对高龄患者有发生致死病例的报告。哺乳期妇女给药期间应停止哺乳，对儿童的安全性尚未确定。
贮藏
密封，置阴凉处。
规格
－－－－
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.